ArticleThe Journal of experimental medicine2017

Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy.

Michelle E LeBlanc et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.